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B-FLOW TWINKLING SIGN IN PREOPERATIVE EVALUATION OF CERVICAL 
LYMPH NODES IN PATIENTS WITH PAPILLARY THYROID CARCINOMA 
 
INTRODUCTION 
 
Papillary thyroid carcinoma is the most common histologic type of differentiated thyroid cancer and 
accounts for 80% of all thyroid cancers [1, 2].	  The disease-specific survival rate of papillary thyroid 
carcinoma is excellent but its recurrence rate is high [2-4].	  Therefore, preoperative evaluations of 
the extent of the primary tumor and the presence of lymph node metastasis are crucial for optimal 
treatment to reduce the recurrence rate. 
 
Incidence 
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer, 
comprising approximately 90% of the 44,670 estimated new cases of thyroid cancer in the United 
States in 2010 [1].	   The disease-specific survival rate of PTC is excellent and may exceed 90% at 10 
years, but its recurrence rate is more than 30% [5-7]. PTC and the follicular variant of PTC have a 
propensity for cervical lymphatic spread that occurs in 20% to 50% of patients on standard review 
of surgical pathologic specimens and in 90% of those examined for micrometastases [3,4]. The 
spread of tumors cells occurs in a predictable pattern that initiates in the perithyroidal lymph nodes 
(LNs) of the central neck and progresses to the LNs of the lateral cervical compartments and the 
superior mediastinum [8,9]. “Skip” metastases to the lateral compartment without central neck 
nodal involvement are rare but do occur [8,9]. Patients with nodal metastasis have higher rates of 
persistent and recurrent disease during postoperative surveillance [9]. Furthermore, lymph node 
metastasis has also been identified as a risk factor for distant metastasis. The impact of nodal 
metastasis on overall survival remains debatable; several studies have demonstrated no difference in 
mortality, while two large population-based studies have shown increased mortality in patients with 
regional LNs metastasis [10-14]. 
 
Detection of Nodal Metastasis 
Several studies have shown that ultrasonography has higher sensitivity than palpation and the other 
diagnostic methods for the detection of cervical metastatic LNs in patients with PTC [15-18]. High 
resolution ultrasonography can detect cervical nodal metastasis in 14% to 20% of PTC patients and 
can detect pathologic nodes as small as 2 to 3 mm without radiation exposure [19,20]. Ultrasound is 
also easily repeatable and has been shown to change the surgical procedure performed in 39% of 
thyroid cancer patients. [21,22]. A dedicated cervical ultrasound to include nodal levels II–VI 
should be performed, to detect nonpalpable LNs metastases in patients undergoing surgical 
evaluation for any thyroid nodule. The sensitivity of cervical ultrasound to detect pathologic LNs in 
PTC patients is higher in the lateral neck (94%) than in the central neck (53% to 55%), and this 
disparity may be considered as additional support for prophylactic central neck dissection [23]. 
Metastatic LNs tend to be large, round, hypoechoic, and hypervascularized with a loss of hilar 
architecture (24-31). In differentiated thyroid cancer, metastatic LNs may also demonstrate specific 
features such as hyperechoic punctuations or microcalcifications and cystic appearance (32-34). 
Confirmation of malignancy of suspicious LN found on US is usually recommended and consists in 
a fine-needle aspiration biopsy (FNAB) for cytology and thyroglobulin determination in the aspirate 
fluid (35). However, the US criteria for metastatic LNs are controversial (36,37). 
In patients with suspected mediastinal disease or with bulky cervical lymphadenopathy, cross-
sectional imaging with CT should be considered as it can aid in the planning of nodal dissection and 
often identify as pathologic level VI and VII lymph nodes within the superior mediastinum that are 
not detected on cervical ultrasound or physical examination. 
 
 
BFI 
B-flow imaging (BFI) is a non-Doppler technique widely used to evaluate carotid artery stenosis 
and other vascular diseases [38, 39]. The main advantage of this technology lies in the direct 
visualization of blood reflectors without the limitations of conventional Doppler technology; this is 
extremely useful in the assessment of complex hemodynamics.  
Recent works [40] had applied the BFI technique for evaluation of thyroid nodules. BFI can identify 
a new sign (the twinkling sign; BFI-TS) in "suspect" PTC nodules, which appeared to be generated 
by microcalcifications and increase the US accuracy in identification of malignant nodules. 
The BFI-TS is a rapidly flashing white light behind such stationary objects as microcalcifications, 
which gives the appearance of movement. 
When an incidental sonographic beam impinges a rough interface composed of sparse reflectors, the 
sign is generated by the phase shift, thereby causing a faint variation of the sonographic beam at the 
interface. The sign is also caused by the increase of pulse duration, which results in multiple 
reflections in the medium. In thyroid nodules these rough interface were the microcalcifications 
formed from aggregates of primary psammoma bodies (PBs); they consist mainly of highly 
reflecting crystalline aggregates of calcium [41].  
The same features described in thyroid nodules, represented by microcalcifications and colloid 
crystals are also present in lymph node metastases. 
 
SURGICAL MANAGEMENT 
Technique 
Central neck dissection is the most common neck dissection completed for patients with PTC and 
can be performed safely and effectively with low complication rates by experienced surgeons. 
Therapeutic central neck dissection is recommended for all patients with clinically evident disease. 
Prophylactic central neck dissection should be considered in order to provide more accurate staging 
in high-risk patients. 
Cervical nodal dissection for PTC should include a systematic or en bloc nodal dissection rather 
than a selective or “berry picking” dissection due to higher rates of persistent and recurrent disease 
with the later approach [42] The ATA consensus statement [19] regarding the terminology and 
classification of the central neck defines the central compartment nodal dissection as all 
perithyroidal and paratracheal soft tissue and lymph nodes with borders extending superiorly to the 
hyoid bone, inferiorly to the innominate artery, and laterally to the common carotid arteries and is 
well described and illustrated by Grodski et al. [43] The inclusion of the level VII nodes in the 
superior mediastinum with the central neck dissection should be noted as this is often a site of 
persistent disease following central neck dissection (ND). Moo et al [44]. compared ipsilateral vs 
bilateral central ND for PTC and concluded that an ipsilateral dissection was sufficient in tumors 
less than 1 cm, while tumors larger than 1 cm required bilateral central ND based on the high 
incidence of contralateral central neck disease in a retrospective analysis of the pattern of nodal 
metastases in surgical specimens. Some additional studies demonstrated that ipsilateral central ND 
was adequate for tumors larger than 1 cm. [45]  If lateral cervical metastases are present in levels 
II–V, a bilateral central nodal dissection should be included with the modified radical ND to remove 
the presumed central neck nodal disease based on described patterns of nodal spread.[46].	  Modified 
radical ND is defined as excision of all LNs routinely removed by radical neck dissection with 
preservation of one or more nonlymphatic structures (the spinal accessory nerve, 
sternocleidomastoid muscle, and internal jugular vein). 
 
Complications 
Complications of central ND include injury to the recurrent laryngeal nerve or the external branch 
of the superior laryngeal nerve, which occurs in 1% to 2% of patients based on several studies 
[45,47-50]. Small retrospective studies have shown that the addition of central compartment 
lymphadenectomy to total thyroidectomy for thyroid cancer has not increased nerve injury rates in 
experienced hands [45,47,48,51]. In cases of reoperative central lymph node dissection after either 
previous thyroidectomy or central node dissection, reports have noted increased nerve injury rates 
ranging from 1% to 12% [52,53].Temporary hypoparathyroidism following central ND occurs in 
14% to 40% of cases depending on the definition of hypoparathyroidism used in the study [54-57] 
The higher incidence of temporary hypoparathyroidism is likely due to the increased incidence of 
parathyroid reimplantation and inadvertent inclusion of parathyroid glands in the nodal dissection. 
Reports are mixed regarding the risk of permanent hypoparathyroidism. A meta-analysis of 
retrospective studies reported a 1.2% incidence as defined by the requirement for calcium 
supplements greater than 6 to 12 months postoperatively; however, none showed a statistically 
significant difference in total thyroidectomy with or without central ND [58]. 
 
Aim Of The Study  
The aim of this study was to determine the presence of BFI-TS in metastatic LNs and to compare it 
with the other ultrasound features in relation to the results obtained from the surgical specimen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
Patients 
Between September 2006 and June 2011, two hundred fifty two patients with known PTC were 
examined, at our institution, for preoperative sonographic evaluation with gray-scale 
ultrasonography (US), color Doppler US and BFI-TS. The patients with suspicious metastatic 
cervical LN at US examination underwent FNAB for cytology and thyroglobulin determination in 
the aspirate fluid. Only eighty-three patients (19 men, 64 women; mean age 52 years  range, 26–79 
years) with at least one metastatic LN were included in our study. 
All patients included in our study underwent surgery, and the final diagnosis was based on the 
results of histologic examination of the resected specimens. 
The mean interval between sonographic examination and surgery was 5.3 days (range, 1–17 days). 
The study was conducted at the Department of Radiology and Endocrinology at the University 
Federico II of Naples and to the Department of Endocrinology at the Second University of Naples, 
according to the principles of the Declaration of Helsinki and approved by the Ethics Committee of 
the University of Molise. Written informed consent was obtained from all subjects.  
 
US and Cytological Examinations 
US, color flow Doppler (CFD) and BFI examinations were performed with LOGIQ 9 GE 
Healthcare (Chalfont St Giles, UK), a commercially available real-time US system, equipped with a 
5 to 14 MHz (M12L) and 2.5 to 7 MHz (7L) linear array transducer. All examinations were 
performed by two blinded radiologists with 6 and 5 years of neck sonography experience separately 
and all data analysis was performed by another investigator. When results of the examiners were 
discordant, agreement was found by conjoint review of clips of the US examinations. 
At gray-scale US, the following six sonographic characteristics were evaluated for all LNs 
examinated: a round shape (ratio of short axis to long axis > 0.5), absence of echogenic hilum, 
abnormal ecogenicity of LN, calcification, cystic change and a peripheral color Doppler pattern.  
Of all cervical LNs were recorded shape, size and location (levels I-VI), on the basis of the 
American Joint Committee on Cancer and the American Academy of Otolaryngology-Head and 
Neck Surgery nodal classification [59,60,61].  
BFI was performed at 10 MHz (M12L) and 7 MHz (7L) with the BFI capability at the level of the 
LNs. PRI was set at 3. BFI gain was not fixed and was adjusted to allow a better visualization of the 
signs. This technique focuses on high flow, with suppression of the tissue signal. BFI images were 
used to evaluate the presence or the absence of the signs. 
The sign was considered positive when at least a twinkling was present in the LNs examined and 
repeatable over time. 
After the US features were assessed, patients underwent a cytological evaluation and findings were 
recorded by a radiologist. US-guided FNA was simultaneously performed by an endocrinologist, a 
radiologist and pathologist. 
Physicians were extremely experienced in the performance of US-guided FNA, with 27- and 22- 
gauge needles; the technique used is described in literature (62,63). A number of three or four 
smears were prepared; the first was air dried and immediately stained with Diff Quik stain 
Inadequate smears were immediately repeated.  
After collection of the cytology samples, each FNAB needle is then washed with 0.1– 0.5 ml of 
normal saline; the washes from all needles are pooled (final volume 0.5–1 ml) and sent to the 
laboratory. Thyroglobulin was measured in fine needle washouts using an immunoradiometric assay 
(IRMA) based on coated tubes with monoclonal antibodies directed against distinct epitopes of the 
molecule of Tg (DYNO test Tg-plus, BRAHMS Diagnostic GmbH, Berlin, Germany). With this 
measurement, analytic sensitivity, defined as the detectable minimum concentration different from 
zero (mean value + 2 standard deviation), and functional sensitivity, defined as the lowest value that 
was measured with the precision of a maximum 20% interassay variance, were 0.08 ng/mL and 0.2 
ng/mL, respectively. [64] 
 
Surgery and Histologic Examination 
All patients underwent thiroidectomy and ipsi or bilateral modified radical neck dissection to 
include levels II-V. All possible measurements were taken to ensure an accurate one-to-one 
comparison between the LNs that were imaged and those that were removed during surgery. After 
US examination, the location of each lymph node was mapped with respect to the surrounding 
anatomic structures (ie, trachea, main vessels, and sternocleidomastoid muscle) and plotted on the 
sketch diagram of the neck. In addition, the surgeons were assisted by a radiologist for correlation 
of the LN location seen on the US images with the LNs seen in the lymphadenectomy specimens. 
After being resected, each LN specimen was fixed in 10% formalin, embedded in paraffin, cut into 
thin slices, and stained with standard hematoxylin-eosin. During histologic examination, two or 
three histologic slices per LN were examined. The final diagnosis of metastatic lymph node 
involvement was made by a pathologist who had 15 years of experience performing histologic 
cervical LN diagnosis. Certain additional features were also recorded such as complete versus 
incomplete metastatic involvement and presence of necrosis and/or calcifications.  
 
US and pathology correlation 
 
To match each LN found at pathological examination to the corresponding node on US, we took 
into account its location, shape, and size. Only LNs that were matched without any doubt between 
US and pathology were taken into account. Multiple LNs in a given neck level on US were taken 
into account only if all LNs of the compartment were either benign or malignant. 
 
Statistical Analyses 
Qualitative variables were compared by using the χ2test. The BFI characteristics of each lymph 
node were registered separately and processed blindly for statistical evaluation. The unit of analysis 
was each lymph node rather than each patient. The value of each visual and qualitative criterion that 
showed the highest diagnostic accuracy in the distinction between benign and metastatic lymph 
nodes was selected as the cutoff value. For each criterion examined, the sensitivity, specificity, 
positive and negative predictive values, and overall accuracy in the differentiation between benign 
and metastatic lymph nodes were calculated. Quantitative data are presented as means ± 1 standard 
deviation. Statistical significance was assumed when the p value was less than 0.05. 
 
 
 
 
RESULTS 
 
A total of 604 LNs were analyzed. 298 out of 604 were metastatic while the remaining 306 were  
benign, according to the histopathologic findings. The minimum diameters of LNs on sonography 
ranged from 2.3 to 13 mm, with mean diameter of metastatic LNs 5,8 mm and the mean diameter of 
nonmetastatic LNs 4.6 mm. No statistical difference was observed between the histopathologically 
determined diameters of metastatic and nonmetastatic LNs (p > 0.05). 
The diagnostic performance of each ultrasound finding in this study is shown in Table 1. 
Most ultrasound features had high specificity and PPV but low sensitivity and NPV. The only 
sonographic characteristic with high specificity and sensitivity values was the BFI-TS. 
The BFI-TS was positive in all LNs with microcalcification at the US examination (93 LNs) and in 
148 LNs (all metastatic) in which microcalcifications were not evident to the US but were 
histologically. 
 Only one LN positive at the BFI and with calcifications at US was a tuberculous node after 
treatment with intranodal macrocalcifications at histological examination  
 
US features 
Total 
lymph 
nodes 
(604) 
Metastatic 
lymph 
nodes (298) 
Sensitivity 
(%) 
Specificity 
(%) 
P PPV NPV 
Round size 
Short to long 
Axis 
(diameter 
ratio > 0.5) 
183 155 52 90.8 
Χ2 131.3 
P 0.0000 
84.7 66 
Abnormal 
Echogenicity 
290 244 81.9 85 
Χ2 270.3 
P 0.0000 
84.1 82.8 
Calcification 94 93 31.2 99.7 
Χ2 109.5 
P 0.0000 
98.9 59.8 
Cystic 
Change 
63 63 21.1 100 
Χ2  72.2 
P 0.0000 
100 56.6 
Absent Hilum 400 274 91.9 58.8 
Χ2 174 
P 0.0000 
68.5 88.2 
Peripheral 
Vascularity 
238 142 47.6 68.6 
Χ2 16.7 
P 0.0000 
59.7 57.4 
BFI-TS 242 241 80.9 99.7 
Χ2 407.9 
P 0.0000 
99.6 84.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
Neck US is highly sensitive for the diagnosis of metastatic LNs in patients with PTC. The 
specificity reported varies from 85 to 90% [65]. A variety of diagnostic criteria have been reported 
to be useful for the distinction between benign and metastatic LNs.  
LN size has been previously described as a criterion for malignancy detection. By comparing three 
lymph node diameters, van den Brekel and coworkers [66] previously concluded that the minimum 
axial diameter is a better criterion than both the maximum axial diameter and the longitudinal 
diameter. The cutoff nodal short-axis diameters range from 5 to 30 mm [67-69]. However, some 
findings indicate that the size criteria used for random patient populations are not optimal for neck 
LNs assessment and that the same cutoff points cannot be used for all levels in the neck [70]. 
Because both reactive and metastatic lymph nodes in level II tend to be larger in patients with head 
and neck cancer . Many authors agree that the size criterion for lymph nodes in level II is larger.  
In our study, a cutoff short-axis diameter of 8 mm was used, yet neither univariate nor multivariate 
analysis results support the diagnostic accuracy of this criterion for neck lymph node classification 
mainly because of its low sensitivity. 
Lymph node shape also has been used as a criterion for the detection of metastatic lymph nodes. In 
some previous studies, metastatic lymph nodes often appeared as round lesions, whereas benign 
nodes are usually flat or oval [71]. In current investigation, this sign has an excellent specificity 
(90.8%) but low sensitivity (52%). Of note, LNs in normal individuals of the parotid and 
submandibular regions  are  often  round  [72].  
The presence of a hyperechoic hilum of the nodes are usually considered strong diagnostic criteria 
for benign lymph nodes [73]. It has been reported that 84%–92% of benign nodes but less than 5% 
of metastatic nodes have a hyperechoic hilum [74]. The absence of fatty hilum is often seen in 
normal individuals, especially in young subjects and LNs located in level V [75]. In our study, the 
metastatic LNs with visible hilum and partial involvement were at high level, while the LN 
metastases at low level showed in  99.5% the absence of hyperechoic hilum. 	  Whereby, an absent 
LN hilum has high sensitivity (91,9%)  but low specificity (58,8%). Whereas, the abnormal LN 
echogenicity had both high sensitivity and specificity (respectively 81,9% and 85%). In our 
experience 54 metastatic LNs (18%) had no abnormal ecogenicity.  Calcification was a specific 
sign but not sensitive criterion. Calcification in metastatic lymph nodes is  characteristic of PTC but 
generally rare. In our results nodal calcifications were detected in only 93 of the 298 metastatic 
LNs.  Similarly, we  found  a  very high specificity (100%) and a low sensitivity (21,1%) for cystic 
appearance.  All LNs with hyperechoic punctuations or a cystic appearance in a patient   with PTC   
should   be   considered   as malignant. 
Assessment of nodal vascularity at color Doppler US is an further criteria for the diagnosis of 
metastatic LNs. It has been noted that benign LNs tend to show hilar vascularity or appear 
avascular [76,77]. In contrast, metastatic nodes tend to have peripheral or mixed (both peripheral 
and hilar) vascularity [78). In our study, color Doppler US vascularity had intermediate specificity 
(68,6%) but low sensitivity (47,6%). These findings correspond to previously published reports that 
the value of color Doppler US cannot compete with that of FNAC in the diagnosis of metastatic 
adenopathy. 
The BFI-TS had the higher specificity and sensitivity (respectively 99,7% and 80.9%) than those of 
the conventional US features. The BFI-TS was positive in all LNs with calcification on US (93 
LNs) and in 148 LNs (all metastatic) in which calcifications were not identified on US. We	  consider	   that	   the	  BFI-­‐TS	   identify	   significantly	  more	  microcalcifications	   than	  B-­‐mode	  US and 
also identify highly reflective and non-calcified structures such as colloidal crystals. Questo	   è	  
avvalorato	  dal	  riscontro	  istologico	  microcalcifications	  and	  colloidal crystals nella sede 	  del	  BFI-­‐TS. 
The BFI-TS has been detected in 6 metastatic LNs resulting negative to the other conventional US 
features . Therefore the presence of BFI in addiction to convetional US increases the sensitivity for 
identifying the suspicious LNs. Its high specificity (99,7%) allows identifying more better the 
suspicious LNs to revaluate by surgery or US-guided FNAC. The limits of the technique consist in  
the influence of pulsatility of main neck vessel and the deep places of examinated LNs. These limits 
could explain the missed detection of  57 LNs (19%) resulted metastatic at istological examination. 
The other limit  is the presence of non metastatic LN calcifications; in fact the  BFI-TS resulted 
false-positive only in a LN with calcification deriving from tuberculosis. Our	  results	  indicate	  that	  this	  technique	  can	  be	  applied	  to	  studies	  of	  cervical	  nodes	  in	  patients	  with	  PTC	  and	  that	  its	  sensitivity	  and	  specificity	  is	  higher	  than	  those	  of	  traditional	  US	  diagnostic	  techniques. 
In conclusion, BFI is a promising imaging technique that can provide assistance in the 
differentiation of benign and metastatic neck LNs in patients with PTC. Our findings suggest that 
BFI can be helpful in the selection of suspicious neck LNs that should be examined at cytologic 
examination or open biopsy for accurate preoperative staging and individual therapy selection.	  However,	  longitudinal	  studies	  on	  a	  large	  population	  are	  required	  to	  verify	  the	  efficacy	  of	  BFI	  in	  the	  diagnosis	  of	  metastatic	  LNs.	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